Page 23 - Sun Pharma

Sun Pharma Q3 PAT doubles to Rs 1,852 cr, rides on record quarterly revenue

The company has repaid debt of about $490 million in 9MFY21; filings for 90 ANDAs await US FDA approval

Sun Pharma gains 6% on good Q3 results, Rs 5.50 per share interim dividend

Analysts had expected the revenues to grow around 6 per cent YoY and Ebitda margins expected to improve 42 bps YoY to 23 per cent

Bright outlook: Sun Pharma to Cipla, drug firms set for Q3 health boost

Analysts expect earnings growth to be in the range of 30-40 per cent for drug firms owing to both domestic recovery as well as strong export opportunities

Sun Pharma rises 3%, hits over 2-year high on steady earnings visibility

The board of directors of Sun Pharma are scheduled to meet on January 29, 2021 to consider and approve Q3 results

BSE Healthcare index hits new high; Sun Pharma, Laurus Labs gain up to 5%

Sun Pharmaceutical Industries hit afresh 52-week high of Rs 568.50, up nearly 4 per cent in the intra-day trade today. It has surged 11 per cent in the past four trading days on the BSE

Sun Pharma rallies 6%, inches towards 52-week high on heavy volumes

In the past three months, Sun Pharma underperformed the market by falling 1 per cent as compared to a 13 per cent rise in the S&P BSE Sensex till Friday

Street concerns ease as Sun Pharma's specialty segment delivers in Q2

Upsides in the stock will depend on sustaining specialty and India sales growth

Sun Pharma gains 10% in two days on healthy September quarter results

The company said that sales of specialty products have improved sequentially with Ilumya and Cequa reaching pre-Covid levels

Sun Pharma's Q2 net profit rises 70% on one-time tax credit

Revenues remain flat, sequential improvement in India and US revenues

Financials lift indices; Sensex ends 504 pts up ahead of US poll outcome

All that happened in the markets today

Sun Pharma closes share buyback offer period; stock jumps 5%

The drug major is looking to expand its specialty business across different regions like Greater China and Japan after having established presence in the US market

Sun Pharma bullish on specialty biz, looks to expand to new geographies

Sun Pharmaceutical Industries Managing Director Dilip Shanghvi said the company''s strategy of developing the specialty business as an additional growth engine has started delivering results

Sun Pharma arm recalls one lot of diabetes drug Riomet ER oral in US

Sun Pharma has said it is voluntarily recalling one lot of Riomet ER oral suspension in the US market, due to the presence of a probable human carcinogen above the acceptable daily intake limit.

Stock picks by Prabhudas Lilladher: Buy Take Solutions, Sun Pharma

Sun Pharma's stock is in a rising trend

Covid-19 prescription: Pharma players shift their focus over the counter

The pandemic pushes pharma companies to look at drugs that held promise in transitioning to over the counter segment

Sun Pharma surges 4%, hits 52-week high; stock rallies 76% from March-low

For the quarter ended June 2020, Sun Pharma reported a surprise loss due to one-time charges.

Pharmacy consolidation may disrupt domestic drug market: Credit Suisse

The report says if chemists are allowed to replace doctor's prescription with a generic drug, firms with high exposure to chronic therapeutic drugs will be impacted more

Sun Pharma, L&T: Stocks that Nilesh Jain of Anand Rathi is bullish on

Sun Pharma's counter has provided a fresh breakout after retesting its rising channel on the daily chart

Lupin, Sun Pharma recalling products in the US market, says USFDA

Leading drug makers Lupin and Sun Pharma are recalling different products in the US, according to the US Food and Drug Administration (USFDA).

Lupin launches Covid-19 drug Favipiravir in India at Rs 49 per tablet

Favipiravir has received authorisation from the Drug Controller General of India (DCGI) for emergency use of its product